Inverna Therapeutics announces the formation of its Scientific Advisory Board consisting of world-renowned leaders in RNA therapeutics and neurodegenerative research
The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.
Inverna Therapeutics awarded grant from the Michael J. Fox Foundation for Parkinson’s research
The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.
Inverna Therapeutics will participate in BIO-Europe 2025
We are excited to participate in BIO-Europe 2025 and are looking forward to connect!
Inverna Therapeutics to showcase its groundbreaking RNA therapeutics platform at Nordic Life Science Days 2025
We are excited to participate in the NLSDays and honored to be selected as a finalist for the Nordic Star Pitch Competition.
Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark
The grant will support development of Inverna’s novel RNA therapy targeting LRRK2 to advance precision medicine approaches for Parkinson’s disease.